Physician profile
Jinsu E James
NPI 1154714426
$1,732.69
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $28.30 · 2022: $313 · 2023: $862 · 2024: $529.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,392.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,391.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $495.34 | 2022-2024 | Darzalex, Tecvayli, Imbruvica |
| Celgene Corporation | $319.17 | 2022-2024 | Pomalyst, Reblozyl |
| Astrazeneca Pharmaceuticals LP | $148.13 | 2023-2024 | Calquence |
| E.R. Squibb & Sons, L.L.C. | $147.72 | 2022-2024 | |
| Karyopharm Therapeutics INC. | $120.03 | 2023-2024 | Xpovio |
| Amgen INC. | $104.77 | 2021-2022 | |
| Abbvie INC. | $82.30 | 2023-2024 | |
| Incyte Corporation | $79.78 | 2022-2024 | Monjuvi |
| Lilly USA, LLC | $52.55 | 2024 | Jaypirca |
| Adc Therapeutics America, INC. | $41.88 | 2023-2024 | |
| Btg International INC. | $38.12 | 2023-2024 | |
| Genzyme Corporation | $30.54 | 2023 | |
| Astellas Pharma US INC | $28.59 | 2023 | Xospata |
| Legend Biotech USA INC. | $24.78 | 2022 | |
| Novartis Pharmaceuticals Corporation | $18.99 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jinsu James listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.